1. Home
  2. CXDO vs CHRS Comparison

CXDO vs CHRS Comparison

Compare CXDO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CXDO

Crexendo Inc.

HOLD

Current Price

$6.91

Market Cap

223.1M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.42

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXDO
CHRS
Founded
1995
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.1M
209.8M
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
CXDO
CHRS
Price
$6.91
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$9.20
$5.51
AVG Volume (30 Days)
457.0K
700.5K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
166.67
472.00
EPS
0.02
N/A
Revenue
$68,167,000.00
N/A
Revenue This Year
$45.26
$73.08
Revenue Next Year
$13.31
$30.94
P/E Ratio
$340.50
N/A
Revenue Growth
12.05
N/A
52 Week Low
$5.26
$0.81
52 Week High
$11.23
$2.62

Technical Indicators

Market Signals
Indicator
CXDO
CHRS
Relative Strength Index (RSI) 40.88 45.98
Support Level $6.54 $1.38
Resistance Level $7.02 $1.74
Average True Range (ATR) 0.44 0.06
MACD -0.07 0.00
Stochastic Oscillator 40.46 47.63

Price Performance

Historical Comparison
CXDO
CHRS

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: